Last reviewed · How we verify
NCT03789162
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
trial in Colorectal Cancer in 850 participants. Completed in 29 May 2025.
31 March 2025
Quick facts
| Lead sponsor | Exact Sciences Corporation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 850 |
| Start date | 20 December 2018 |
| Primary completion | 31 March 2025 |
| Estimated completion | 29 May 2025 |
| Sites | 45 locations across Canada, United States |
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Exact Sciences Corporation
Who can join
40 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for the detection of colorectal cancer (CRC).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Next-generation Multi-target Stool DNA Panel Accurately Detects Colorectal Cancer and Advanced Precancerous Lesions.
Gagrat ZD, Krockenberger M, Bhattacharya A, Gagrat BZ, et al · · 2024 · cited 19× · PMID 38224564 · DOI 10.1158/1940-6207.capr-23-0285 -
Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer.
Imperiale TF, Gagrat ZD, Krockenberger M, Porter K, et al · · 2024 · cited 5× · PMID 39280922 · DOI 10.1016/j.gastha.2024.05.002
Verify or expand the search:
- PubMed search for NCT03789162
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Exact Sciences Corporation trials
Trials by the same sponsor.
- NCT05246839 — Informed Choice - Compass · terminated
- NCT05210283 — CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer · active not recruiting
- NCT04473625 — Stool Collection Sub-Study of Exact Sciences Protocol 2018-01 · completed
- NCT04395391 — Home Usability Study of the SARS-CoV-2 (COVID-19) Test · completed
- NCT04213326 — Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03789162 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Exact Sciences Corporation
- Last refreshed: 29 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03789162.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing